Plain-English translation of NCT06556394 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new medication called to see if it is safe and tolerable in people with ALS caused by a specific genetic mutation (SOD1). The medication is given as an injection into the fluid around the spine. Researchers want to understand how the treatment works in the body and whether it might help slow or manage this serious nerve disease.
ALS is a devastating disease that progressively weakens muscles, and there are very few effective treatments available. This trial exists to explore whether this new medication could offer hope to patients with the genetic form of ALS caused by SOD1 mutations.
You likely qualify if…
You likely don't qualify if…
Participants will receive either the medication or a placebo (an inactive substance) as an injection into the fluid surrounding the spine. Most participants (3 out of 4) will receive the actual medication, while 1 out of 4 will receive placebo; neither you nor the researchers will know which you're getting. The study will test different doses gradually across groups to ensure safety, and you'll have regular visits and tests to monitor how your body responds.
AI-generated summary from trial data · Jun 1, 2026 · Not medical advice
China